CN101822706B - Gynostemma pellet preparation for preventing subclinical mastitis and preparation method thereof - Google Patents
Gynostemma pellet preparation for preventing subclinical mastitis and preparation method thereof Download PDFInfo
- Publication number
- CN101822706B CN101822706B CN2010101531739A CN201010153173A CN101822706B CN 101822706 B CN101822706 B CN 101822706B CN 2010101531739 A CN2010101531739 A CN 2010101531739A CN 201010153173 A CN201010153173 A CN 201010153173A CN 101822706 B CN101822706 B CN 101822706B
- Authority
- CN
- China
- Prior art keywords
- gynostemma
- preparation
- coating
- herb gynostemmae
- gynostemmae pentaphylli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a gynostemma pellet preparation for preventing subclinical mastitis and a preparation method thereof, which belong to the field of veterinary medicine; and the preparation is prepared from gynostemma, starch, dextrin, cellulose acetate and polyethylene glycol 1500 with different weights, improves immunity by increasing the number of white blood cells, enhancing T cells and promoting the production of macrophages, prevents and cures mastitis, and has the advantages of high curing effect, no toxin, no side effect and no residue.
Description
Affiliated technical field
The invention belongs to the veterinary drug technology, relate generally to the gynostemma pellet preparation and the method for preparing that are used to prevent and treat bovine subclinical mastitis.
Background technology
Mammitis of cow has another name called bovine mastitis, is a kind of commonly encountered diseases and the frequently-occurring disease of milch cow.Although carried out years of researches, but still be a kind of one of the highest disease of cost of treating in the raising dairy cattle.The generation of mastitis and pathogenic microorganism and environment have direct relation, and the development that it seriously hampers the milk cattle cultivating industry causes very big loss to the raiser.
Present Therapeutic Method generally is to be main with the treatment of oral, perfusion, injection of antibiotics; Though treat evident in efficacy; Truly have residue problem,, abandoning the milk phase of different time all arranged according to different antibiotic by Ministry of Agriculture's regulation; Abandoning interior milk of milk phase can not sell, and causes the economic loss of discarding milk after the medication.Because mastitis is a kind of commonly encountered diseases; Almost every cow head all can take place once even the different mastitis of several disease in lactation period, and the lighter's milk production descends, milk is discarded, downright bad, the atrophy of severe patient breast district's suppuration; Make mammary gland forever lose milking capacity, in addition superseded or dead.So treat after being ill with it,,, improve the cowboying economic benefit to reduce the sickness rate of mastitis greatly not as strengthening prevention in the daily feeding process.And existing to be used to prevent the medicament of usefulness or additive majority be Chinese powder medicine or example hydrochloric acid levamisole, is not DeGrain, is exactly drug residue, stays hidden danger for people's health.
Summary of the invention
The object of the present invention is to provide the gynostemma pellet preparation and the method for preparing that are used to prevent and treat bovine subclinical mastitis; Produce through leukocyte increasing number, enhancing T cell, promotion macrophage, reach the purpose that improves immunity, prevention and treatment latent mammitis, curative effect height, drug residue free; Adopt pellet preparations technology, can make medicine have the sustained-release and controlled release ability, release is stable, and bioavailability is high.
Technical scheme of the present invention is:
Be used to prevent and treat the gynostemma pellet preparation of bovine subclinical mastitis, be prepared from following materials of weight proportions: Herb Gynostemmae Pentaphylli 10-50 part,, starch 1-50 part, dextrin 1-50 part, cellulose acetate 1-10 part, polyethylene glycol 1500 1-5 part.
The present invention also provides the method for preparing of the gynostemma pellet preparation that is used to prevent and treat bovine subclinical mastitis, comprises the steps:
Take by weighing the raw material that contains above-mentioned weight ratio; Herb Gynostemmae Pentaphylli powder is broken into fine powder adds 20 times of 80% ethanol, put 90 ℃ of supersound extraction 1h in the ultrasonic extraction extractor, extract altogether 3 times, merging filtrate reclaims ethanol, and vacuum drying promptly gets Herb Gynostemmae Pentaphylli and extracts powder; Cellulose acetate and polyethylene glycol 1500 are added an amount of dissolve with ethanol make into coating solution; Herb Gynostemmae Pentaphylli is extracted powder and starch, dextrin mix homogeneously, cross 20 mesh sieve system wet granulars, put wet granular in the coating pan behind the rolling 10-30min with 70% alcoholic solution; Uncap, heat 60 ℃, rolling 1h; Take out micropill and put drying in oven, more exsiccant micropill is put into coating pan, spray into coating solution; Coating until coating weightening finish 10%-20%, promptly gets gynostemma pellet.
Advantage of the present invention and beneficial effect are: through the leukocyte increasing number, strengthen the T cell, promote macrophage to produce, reach raising immunity, prevention and treatment mastitis have the drug effect height, have no side effect, the advantage of noresidue; Adopt cellulose acetate and polyethylene glycol 1500 as micropill microporous membrane coating material; Water can penetrate microporous membrane; Dissolving medicine wherein forms the saturated solution of medicine, in micropill, reach the sustained-release and controlled release effect through micropore to external diffusion release, and release is stable; Bioavailability is high, can reach 5-6h at gastric transit time.
The specific embodiment
Describe the present invention for example below.
Embodiment 1:
By weight taking by weighing 50 parts of Herb Gynostemmae Pentaphylli, 30 parts of starch, 20 parts in dextrin, 7 parts of cellulose acetate, 2.5 parts of polyethylene glycol 1500s.Herb Gynostemmae Pentaphylli powder is broken into fine powder adds 20 times of 80% ethanol, put 90 ℃ of supersound extraction 1h in the ultrasonic extraction extractor, extract altogether 3 times, merging filtrate reclaims ethanol, and vacuum drying promptly gets Herb Gynostemmae Pentaphylli and extracts powder; Cellulose acetate and polyethylene glycol 1500 are added an amount of dissolve with ethanol make into coating solution; Herb Gynostemmae Pentaphylli is extracted powder and starch, dextrin mix homogeneously, cross 20 mesh sieve system wet granulars, put wet granular in the coating pan behind the rolling 10-30min with 70% alcoholic solution; Uncap, heat 60 ℃, rolling 1h; Take out micropill and put drying in oven, more exsiccant micropill is put into coating pan, spray into coating solution; Coating until coating weightening finish 10%-20%, promptly gets gynostemma pellet.
Embodiment 2:
By weight taking by weighing 20 parts of Herb Gynostemmae Pentaphylli, 50 parts of starch, 25 parts in dextrin, 8 parts of cellulose acetate, 3 parts of polyethylene glycol 1500s.Herb Gynostemmae Pentaphylli powder is broken into fine powder adds 20 times of 80% ethanol, put 90 ℃ of supersound extraction 1h in the ultrasonic extraction extractor, extract altogether 3 times, merging filtrate reclaims ethanol, and vacuum drying promptly gets Herb Gynostemmae Pentaphylli and extracts powder; Cellulose acetate and polyethylene glycol 1500 are added an amount of dissolve with ethanol make into coating solution; Herb Gynostemmae Pentaphylli is extracted powder and starch, dextrin mix homogeneously, cross 20 mesh sieve system wet granulars, put wet granular in the coating pan behind the rolling 10-30min with 70% alcoholic solution; Uncap, heat 60 ℃, rolling 1h; Take out micropill and put drying in oven, more exsiccant micropill is put into coating pan, spray into coating solution; Coating until coating weightening finish 10%-20%, promptly gets gynostemma pellet.
Embodiment 3:
By weight taking by weighing 40 parts of Herb Gynostemmae Pentaphylli, 30 parts of starch, 30 parts in dextrin, 4 parts of cellulose acetate, 1.5 parts of polyethylene glycol 1500s.Herb Gynostemmae Pentaphylli powder is broken into fine powder adds 20 times of 80% ethanol, put 90 ℃ of supersound extraction 1h in the ultrasonic extraction extractor, extract altogether 3 times, merging filtrate reclaims ethanol, and vacuum drying promptly gets Herb Gynostemmae Pentaphylli and extracts powder; Cellulose acetate and polyethylene glycol 1500 are added an amount of dissolve with ethanol make into coating solution; Herb Gynostemmae Pentaphylli is extracted powder and starch, dextrin mix homogeneously, cross 20 mesh sieve system wet granulars, put wet granular in the coating pan behind the rolling 10-30min with 70% alcoholic solution; Uncap, heat 60 ℃, rolling 1h; Take out micropill and put drying in oven, more exsiccant micropill is put into coating pan, spray into coating solution; Coating until coating weightening finish 10%-20%, promptly gets gynostemma pellet.
The gynostemma pellet preparation of control mammitis of cow is carried out following test:
1, content of effective determination test:
Herb Gynostemmae Pentaphylli mainly contains Saponin, polysaccharide, flavone, aminoacid, vegetable protein, materials such as alcohol, pigment, organic acid, cellulose, chlorophyll, trace element now.Gypenoside has the ability of enhancing human body immunity power widely; And can suppress rejection obviously the leukocyte increasing number, improve the T lymphocyte, strengthen splenocyte breeder reaction, the T cell in the mixed lymphocytes is had potentiation, and can promote to secrete macrophage.Have the tumor of inhibition, defying age, blood fat reducing, enhancing immunity and protection action of the heart.
Gypenoside has the dammarane type four-ring triterpenoid structure identical with the ginsenoside for the summation of the multiple Saponin that extracts, so be that the standard substance analysis is analyzed three batches of finished products with ginsenoside Rb1.
| Lot number | Total saponin content g/g | RSD％ |
| 080201 | 0.276 | 1.21 |
| 080202 | 0.275 | 1.32 |
| 080203 | 0.271 | 1.18 |
Above-mentioned three batches of preparations are same preparation technology embodiment product, and every g finished product contains Herb Gynostemmae Pentaphylli crude drug 6g, and the Herb Gynostemmae Pentaphylli crude drug contains total Saponin amount and is approximately 4%-6%.Can reach a conclusion by last data: owing to adopted ultrasonic extraction that extraction ratio can be reached more than 4.5% on the technology of the present invention, not loss basically, effective component extraction rate is high, and process stabilizing is reliable.
2, controlled release dissolution test
Get three batches of preparation lot numbers 080201,080202,080203 of the present invention and be test group; By same preparation process, not carrying out controlled-release material coating process is produced three batches of products is matched group lot number 001,002,003 in addition.Carry out assay by quality standard respectively, draw the effective ingredient total saponin content of gynostemma pentaphyllum.By " People's Republic of China's veterinary drug allusion quotation 2005 editions " slow release, controlled release and slowbreak preparation guideline, the test of vitro drug release degree, put in the dissolution appearance every at a distance from 30min sampling carrying out assay with survey total content and compare and confirm medicine stripping percentage ratio.
Test group and matched group dissolution determination be % as a result
Conclusion: can know that from above-mentioned test data matched group does not carry out controlled release coat, medicine reaches about 2 hours and discharges the peak; Test group peaks at 5-6h through the controlled-release material coating, and drug release is even gently, can be near the constant release medicine.This is owing to adopting the microporous membrane coating material on the technology when medicine contacts with gastro-intestinal Fluid; The water solublity porogen that exists on the film is met the water section dissolving or is come off; On coating membrane, form sightless micropore of countless naked eyes or crooked trail, make the clothing film have permeability, the liquid in the gastrointestinal tract infiltrates in the film through these micropores; The medicine of solution tablet in-core arrives to a certain degree; The drug solution of sheet in-core just produces certain osmotic pressure, because the difference of the inside and outside osmotic pressure of film, drug molecule just discharges to the film external diffusion through these micropores.Medicine descends the osmotic pressure in the sheet to the result of film external diffusion, and moisture is again to get into dissolved substance in the film, so repeatedly, as long as there is sink condition in medicine inside and outside keeping saturated concentration and film in the film, then can obtain zero level or near the drug release of zero level speed.Coating membrane is not destroyed in gastrointestinal tract, is excreted by intestinal at last.
3, stability test: the condition held 12 months that three batches of products is packaged in 25 ℃ ± 2 ℃ of temperature, relative humidity 60% ± 10% by finished product; Sampling in per 3 months once detected by stable high spot reviews project respectively at 0 month, 3 months, 6 months, 9 months, 12 months.After 12 months, carry out outward appearance, content detection respectively at sampling in 18 months, 24 months.
Conclusion: character of the present invention, content are all very stable, meet " People's Republic of China's veterinary drug allusion quotation 2005 editions " related request.
4, safety testing
Mouse gavaging preparation 10g/kg of the present invention is equivalent to 100 times of the positive usual amounts of milch cow, does not have dead in 72 hours; Feed 10g/kg every day, be equivalent to 100 times of the positive usual amounts of milch cow, continuous 1 month, ordinary circumstance, body weight gain, food-intake, blood, routine urinalysis and pathology blood examination were looked into all no abnormal.
5, the control mammitis of cow test of pesticide effectiveness
1. test method: Fructus Pruni forestry and animal husbandry cattle farm is used California, USA mammitis of cow detectable (CMT) to detect to choose " ++ " below negative and suffer from 200 of latent mammitis cows in milk in Harbin, is divided into test group and matched group, every group respectively 100.Feed with a kind of feedstuff two groups of every days, and test group adds feeds preparation 50g/ day/head of the present invention, logotype 5 days.Use CMT to detect after January.
Conclusion: 57 of negative cattle, 43 of ill cattle before the matched group test, 54 of the negative cattle in test back, 46 of ill cattle do not see and take a favorable turn.58 of negative cattle, 42 of ill cattle before the test group test, 92 of the negative cattle in test back, 8 of ill cattle, negative conversion rate 81.0%.Samely feed, under the condition of environment; Explain that the present invention has fairly obvious preventive effect to mammitis of cow; Test group detects ill cattle and has turned out cloudy or alleviated disease in various degree after test, explain that the present invention is remarkable in effect aspect the latent mammitis treatment.And what the present invention used is the natural medicinal plant extract; With Herb Gynostemmae Pentaphylli total glycosides enhancing human body immunity power is the mechanism of action; Pharmacology is clear and definite; Bioavailability is high, Drug resistance, the drug residue of having avoided simultaneously using antibiotic to bring, abandons damnous shortcoming of milk phase, and milk cattle cultivating is already had huge economic and social benefit.
Claims (2)
1. gynostemma pellet preparation that is used to prevent and treat bovine subclinical mastitis, it is characterized in that: it is that following materials of weight proportions is prepared from: Herb Gynostemmae Pentaphylli 10-50 part, starch 1-50 part, dextrin 1-50 part, cellulose acetate 1-10 part, polyethylene glycol 1500 1-5 part.
2. a gynostemma pellet formulation preparation method that is used to prevent and treat bovine subclinical mastitis as claimed in claim 1 is characterized in that following steps: take by weighing the raw material that contains above-mentioned weight ratio; Herb Gynostemmae Pentaphylli powder is broken into fine powder adds 20 times of 80% ethanol, put 90 ℃ of supersound extraction 1h in the ultrasonic extraction extractor, extract altogether 3 times, merging filtrate reclaims ethanol, and vacuum drying promptly gets Herb Gynostemmae Pentaphylli and extracts powder; Cellulose acetate and polyethylene glycol 1500 are added an amount of dissolve with ethanol make into coating solution; Herb Gynostemmae Pentaphylli is extracted powder and starch, dextrin mix homogeneously, cross 20 mesh sieve system wet granulars, put wet granular in the coating pan behind the rolling 10-30min with 70% alcoholic solution; Uncap, heat 60 ℃, rolling 1h; Take out micropill and put drying in oven, more exsiccant micropill is put into coating pan, spray into coating solution; Coating until coating weightening finish 10%-20%, promptly gets gynostemma pellet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101531739A CN101822706B (en) | 2010-04-23 | 2010-04-23 | Gynostemma pellet preparation for preventing subclinical mastitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101531739A CN101822706B (en) | 2010-04-23 | 2010-04-23 | Gynostemma pellet preparation for preventing subclinical mastitis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101822706A CN101822706A (en) | 2010-09-08 |
| CN101822706B true CN101822706B (en) | 2012-05-30 |
Family
ID=42687009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101531739A Expired - Fee Related CN101822706B (en) | 2010-04-23 | 2010-04-23 | Gynostemma pellet preparation for preventing subclinical mastitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101822706B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110801493A (en) * | 2019-07-08 | 2020-02-18 | 安徽牧春堂天然药物研究开发有限公司 | Traditional Chinese medicine microcapsule for preventing and treating cow subclinical mastitis and preparation method thereof |
| CN113439804B (en) * | 2020-03-24 | 2023-03-31 | 内蒙古优然牧业有限责任公司 | Gynostemma pentaphylla composition for obese cows in late lactation period and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1115651A (en) * | 1994-07-28 | 1996-01-31 | 叶根火 | Gynostemma pentaphylla granule |
-
2010
- 2010-04-23 CN CN2010101531739A patent/CN101822706B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1115651A (en) * | 1994-07-28 | 1996-01-31 | 叶根火 | Gynostemma pentaphylla granule |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101822706A (en) | 2010-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101664421B (en) | Traditional Chinese biological preparation for preventing and treating livestock diarrhea and preparation method and feedstuff thereof | |
| CN106728000A (en) | A kind of macleaya cordata baikal skullcap root composition and its application for veterinary drug or medicated feed additive | |
| CN104304679B (en) | A kind of B B-complex C, E immune polysaccharide microemulsion preparation and its preparation method and application | |
| CN105287790B (en) | A kind of fevervine extract and its application | |
| CN101664437B (en) | Traditional Chinese medicine for treating coccidiosis and preparation method and application thereof | |
| TW391878B (en) | Pharmaceutical composition or feedstuff comprising at least one of rosa roxburghii, artemisiae argyi folium and brassica oleracea var. capitata l. | |
| RU2624868C2 (en) | Preparation method of the complex gel for mastitis treatment and prevention in cows and complex gel on its basis | |
| CN102048785B (en) | Application of eupatorium adenophorum spreng in preparation of veterinary medicine or feed additive | |
| CN101822706B (en) | Gynostemma pellet preparation for preventing subclinical mastitis and preparation method thereof | |
| CN109007344A (en) | A kind of compound feed additive of anti-cow heat stress and preparation method thereof | |
| CN103127198B (en) | Combined drug for treating piglet's yellow-white dysentery | |
| CN106620668A (en) | Compound tilmicosin solid dispersing agent and preparation method thereof | |
| CN104161208A (en) | Feed additive for preventing chicken bacterial diseases, preparation method and application thereof | |
| CN102614294A (en) | Compound amoxicillin suspension injection and preparation method thereof | |
| CN113967243B (en) | Fermented traditional Chinese medicine preparation for preventing and treating diarrhea of poultry and preparation method thereof | |
| CN110604757A (en) | Compound preparation for strengthening body resistance and detoxifying, and preparation method and application thereof | |
| CN101721437B (en) | Preparation method of medicine composition used for treating chronic pharyngitis | |
| CN105770054A (en) | Pharmaceutical composition for preventing and treating chicken coccocidiosis, additive and feed | |
| CN105213360B (en) | Application of the citric acid iodine in the medicine for preparing treatment livestock and poultry disease of digestive system | |
| CN102068536B (en) | Compound Chinese medicinal particles and application thereof in preparation of medicament for preventing and treating pig digestive tract disease | |
| CN111544570B (en) | Antiviral preparation added with antibacterial peptide and preparation method thereof | |
| CN117244037B (en) | Composition for preventing and treating calf transfer transportation stress and preparation method thereof | |
| RU2524664C1 (en) | Method of prevention of mass gastrointestinal and respiratory diseases of suckling pigs | |
| CN113244220A (en) | Application of potassium dehydroandrographolide succinate in preparation of veterinary drug for treating cow mastitis and potassium dehydroandrographolide succinate veterinary drug | |
| CN102247390A (en) | Medicine for treating bacterial air sacculitis in livestock and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yue Kuizhong Inventor after: Lian Yongquan Inventor after: Gao Shuling Inventor after: Zhang Xiang Inventor after: Xu Zhihui Inventor before: Yue Kuizhong Inventor before: Zhang Xiang Inventor before: Xu Zhihui |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: YUE KUIZHONG ZHANG XIANG XU ZHIHUI TO: YUE KUIZHONG LIAN YONGQUAN GAO SHULING ZHANG XIANG XU ZHIHUI |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 Termination date: 20200423 |